2021 Annual Business Report

2022 Outlook

In 2022, Valneva expects to continue investing strongly in its R&D programs and increase vaccine sales, subject to regulatory approval of VLA2001.

2022  Outlook

Our Financials & Outlook

2022 Financial Guidance

  • Total revenues between €430 to €590 million expected, including:
    • €350 to €500 million of COVID-19 vaccine sales, subject to regulatory approvals and deliveries of VLA2001[1],
    • €60 to €70 million of other vaccine sales
    • Approximately €20 million of Other Revenues (revenues from collaborations, licensing and services)
  • R&D expenses expected between €160 million and €200 million

1 Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001